Kesimpta (ofatumumab)
Multiple Sclerosis
ApprovedCommercial
Key Facts
About Genmab
Genmab is a leading biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer. Founded in 1999 and headquartered in Copenhagen, Denmark, the company has established itself as a pioneer in antibody engineering with proprietary technology platforms including DuoBody and HexaBody. Genmab has multiple approved products generating significant revenue and maintains strategic partnerships with major pharmaceutical companies including Janssen, AbbVie, and Roche.
View full company profileTherapeutic Areas
Other Multiple Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Zeposia (ozanimod) | Bristol Myers Squibb | Commercial |
| Copaxone (glatiramer acetate) | Teva Pharmaceutical Industries | Commercial |
| Multiple Sclerosis Portfolio | Biogen | Commercial |
| Glatiramer Acetate (Generic Copaxone) | Dr. Reddy's Laboratories | Approved |
| Glatiramer Acetate | Cipla | Commercial |
| Interferon β-1a | Bachem | Commercial |
| KYV-101 | Kyverna Therapeutics | Phase 1/2 |
| Azer-cel (PBCAR0191) | Precision BioSciences | Phase 1/2 |
| CYMS101 | FibroBiologics | Pre-clinical / Limited Clinical |